Charles Mills, MD
Rheumatology · Farmington, ARNPI 1689659674
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 443 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Amgen at 27.3% of the total. Reporting peaked in 2019 at $1,853 and has fallen 54.6% since, to $842 in 2025.
Across 443 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AbbVie$2K
- UCB, Inc.$751
- GSK$530
- Johnson & Johnson$435
- Pfizer$426
- plus $1K from 24 others
What the payments were for
- Food & beverage$7,08799%
- Education$1051%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 108 | $1,962 |
| AbbVie | 126 | $1,766 |
| UCB, Inc. | 36 | $751 |
| GSK | 35 | $530 |
| Johnson & Johnson(2 entities) | 29 | $435 |
| Pfizer | 30 | $426 |
| Lilly USA, LLC | 16 | $282 |
| Novartis | 9 | $133 |
| Radius Health, Inc. | 5 | $103 |
| Fresenius Kabi USA, LLC | 5 | $83 |
| Bristol Myers Squibb | 4 | $72 |
| Boehringer Ingelheim | 5 | $70 |
| ANI Pharmaceuticals, Inc. | 3 | $60 |
| Regeneron Healthcare Solutions, Inc. | 4 | $59 |
| Sanofi | 3 | $50 |
| Merck | 3 | $46 |
| Genentech USA, Inc. | 2 | $46 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Novo Nordisk | 3 | $44 |
| Mallinckrodt Hospital Products Inc. | 2 | $35 |
| Dexcom, Inc. | 2 | $33 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Antares Pharma, Inc. | 1 | $18 |
| IBSA Pharma Inc. | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| United Therapeutics Corporation | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Bimzelx$110
How this compares
$7,193 in reported general payments places this provider in the 60th percentile of 48 rheumatology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 119 | $794,694 |
| Enbrel SureclickEtanercept | 68 | $500,887 |
| Humira(Cf) PenAdalimumab | 64 | $442,893 |
| Humira PenAdalimumab | 41 | $283,902 |
| KevzaraSarilumab | 43 | $206,268 |
| Orencia ClickjectAbatacept | 24 | $137,388 |
| EnbrelEtanercept | 19 | $133,854 |
| BenlystaBelimumab | 24 | $108,038 |
| Humira(Cf)Adalimumab | 13 | $88,550 |
| Taltz AutoinjectorIxekizumab | 12 | $81,657 |
| Cimzia (2 Pack)Certolizumab Pegol | 13 | $74,731 |
| Hydroxychloroquine Sulfate | 264 | $10,718 |
| MethotrexateMethotrexate Sodium | 409 | $8,043 |
| EliquisApixaban | 12 | $7,826 |
| Leflunomide | 110 | $4,594 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $1,766 | $883,245132 claims |
| SanofiKevzara | $50 | $206,26843 claims |
| AmgenEnbrel | $1,962 | $133,85419 claims |
| GSKBenlysta | $530 | $108,03824 claims |
| UCB, Inc.Cimzia (2 Pack) | $751 | $74,73113 claims |
| PfizerEliquis | $426 | $7,82612 claims |
| Fresenius Kabi USA, LLCSodium Chloride | $83 | $9122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 48 rheumatology providers in Arkansas.
Other rheumatology in Farmington
- Russell BranumFort Smith$102K
- Cummins LueLittle Rock$76K
- Shailendra SinghSearcy$67K
- Christopher SonntagFayetteville$32K
- Jasen ChiLittle Rock$30K
- Richard HoukLittle Rock$25K
- Noha MohamedConway$19K
- Columbus BrownLittle Rock$18K
- David PetrosFayetteville$17K
- Renee Peterkin-MccalmanLittle Rock$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.